Similarly, how can regulators design a system that focuses oversight on areas where genuine hazards require practical risk assessment and management?
The question for policymakers, then, is what would a successful, science-based regulatory regime look like for innovations produced with recombinant DNA and gene editing techniques? Similarly, how can regulators design a system that focuses oversight on areas where genuine hazards require practical risk assessment and management? The past half-century offers a few simple lessons.